{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:36:57Z","timestamp":1791041817925,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Primary aldosteronism is present in \u224810% of hypertensives. We previously performed a microarray assay on aldosterone-producing adenomas and their paired zona glomerulosa and fasciculata. Confirmation of top genes validated the study design and functional experiments of zona glomerulosa selective genes established the role of the encoded proteins in aldosterone regulation. In this study, we further analyzed our microarray data using AmiGO 2 for gene ontology enrichment and Ingenuity Pathway Analysis to identify potential biological processes and canonical pathways involved in pathological and physiological aldosterone regulation. Genes differentially regulated in aldosterone-producing adenoma and zona glomerulosa were associated with steroid metabolic processes gene ontology terms. Terms related to the Wnt signaling pathway were enriched in zona glomerulosa only. Ingenuity Pathway Analysis showed \"NRF2-mediated oxidative stress response pathway\" and \"LPS (lipopolysaccharide)\/IL-1 (interleukin-1)\u2013mediated inhibition of RXR (retinoid X receptor) function\" were affected in both aldosterone-producing adenoma and zona glomerulosa with associated genes having up to 21- and 8-fold differences, respectively. Comparing<jats:italic>KCNJ5<\/jats:italic>-mutant aldosterone-producing adenoma, zona glomerulosa, and zona fasciculata samples with wild-type samples, 138, 56, and 59 genes were differentially expressed, respectively (fold-change &gt;2;<jats:italic>P<\/jats:italic>&lt;0.05).<jats:italic>ACSS3<\/jats:italic>, encoding the enzyme that synthesizes acetyl-CoA, was the top gene upregulated in<jats:italic>KCNJ5<\/jats:italic>-mutant aldosterone-producing adenoma compared with wild-type.<jats:italic>NEFM<\/jats:italic>, a gene highly upregulated in zona glomerulosa, was upregulated in<jats:italic>KCNJ5<\/jats:italic>wild-type aldosterone-producing adenomas.<jats:italic>NR4A2<\/jats:italic>, the transcription factor for aldosterone synthase, was highly expressed in zona fasciculata adjacent to a<jats:italic>KCNJ5<\/jats:italic>-mutant aldosterone-producing adenoma. Further interrogation of these genes and pathways could potentially provide further insights into the pathology of primary aldosteronism.<\/jats:p>","DOI":"10.1161\/hypertensionaha.116.08033","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T03:19:32Z","timestamp":1477365572000},"page":"1424-1431","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues"],"prefix":"10.1161","volume":"68","author":[{"given":"Junhua","family":"Zhou","sequence":"first","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lam","sequence":"additional","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna G.","family":"Neogi","sequence":"additional","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles S.H.","family":"Yeo","sequence":"additional","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.B.","family":"Azizan","sequence":"additional","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris J.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine &amp; Dentistry, Queen Mary University of London, United Kingdom (J.Z., M.J.B.); Clinical Pharmacology Unit, Department of Medicine, University of Cambridge (J.Z.), University of Cambridge Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science (B.L., G.S.H.Y.), Cambridge University Hospitals NHS Foundation Trust (S.G.N.), Addenbrooke's Hospital, United..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/162804"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2805"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.33549\/physiolres.930000.49.241","article-title":"Impaired insulin action in primary hyperaldosteronism.","volume":"49","author":"Widimsk\u00fd J","year":"2000","unstructured":"Widimsk\u00fd J, Sindelka G, Haas T, Pr\u00e1zn\u00fd M, Hilgertov\u00e1 J, Skrha J. Impaired insulin action in primary hyperaldosteronism. Physiol Res. 2000;49:241\u2013244.","journal-title":"Physiol Res"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505529112"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198785"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2716"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0836"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.150318"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.100438"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.188532"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02051"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt484"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062399"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1085"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1309"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1915"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000025"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1734"},{"issue":"10","key":"e_1_3_4_20_2","first-page":"618","article-title":"Putative calcium-sensitive genes, VSNL1 and ANO4, are up-regulated in human zona glomerulosa cells and may play a role in regulation of aldosterone production.","volume":"28","author":"Maniero C","unstructured":"Maniero C, Zhou J, Azizan EAB, McFarlane I, Neogi SG, Brighton CA, Galietta L, Scudieri P, Brown MJ. Putative calcium-sensitive genes, VSNL1 and ANO4, are up-regulated in human zona glomerulosa cells and may play a role in regulation of aldosterone production. J Human Hyper 28(10):618\u2013618.","journal-title":"J Human Hyper"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03419"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01733"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2965"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1470795"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn615"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.158543"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510073"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0037"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1298"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1680087"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1453"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/10715762.2010.507670"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000284"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346549"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835ba77e"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(89)90163-9"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90200-7"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M500134-JLR200"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.002014"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M013342"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.12.023"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220275"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq029"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.09.011"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1102"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.11.022"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.04.022"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1560477"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.116.08033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T20:43:28Z","timestamp":1749674608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.116.08033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.116.08033"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.116.08033","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}